glp-1/gip receptor agonists GLP-1 are increasingly used to treat type 2 diabetes and obesity, and trials have shown reductions in cardiovascular risk and slowing of kidney failure. Adverse events are mostly gastrointestinal IUPHAR review: From foe to

Dipeptidyl peptidase-4 inhibitor sitagliptin prevents high glucoseinduced apoptosis via activation of AMPactivated protein kinase in endothelial cells

Start Your Compounding Workflow Before You Leave Denver Explore eNavvis dermatology compound templatesmelasma, alopecia, acne, wound care, anti-agingwith transparent cash pricing across PCAB-accredited pharmacies

Metabolic dysfunctionassociated steatohepatitis (MASH) is not just a liver condition - its deeply connected to obesity, insulin resistance, and cardiovascular disease

FcRI receptors are expressed in mast cells (MCs), basophils, DCs, and eosinophils, but are also present in other cells, such as airway smooth muscle cells (ASM), epithelial, and endothelial cells